Short answer
Travere Therapeutics, Inc. (TVTX) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $170M (up 48.2% year over year) with net income of −$35M.
Q2 2026 key financials · XBRL
- Revenue
- $170M
- +48.2% YoY · +33.3% QoQ
- Net income
- −$35M
- −172.8% YoY · +6.2% QoQ
- Operating margin
- 2.3%
- EPS (diluted)
- −$0.38
- −171.4% YoY · +5.0% QoQ
Source: XBRL data from the Travere Therapeutics, Inc. (TVTX) Q2 2026 10-Q on SEC EDGAR. USD.
Travere Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $169.6M, up $55.1M YoY from $114.4M, driven by FILSPARI sales
- FILSPARI revenue $141.1M, up $69.2M YoY; tiopronin $20.3M, down $2.7M
- Operating expenses $165.6M, up $38.5M YoY; R&D $60.3M and SG&A $96.1M
- Cash deployment: $112.5M upfront payment for civorebrutinib license in July 2026
- HARMONY enrollment restarted in Q1 2026; topline pegtibatinase data anticipated in second half of 2027
Risk Factors
- FSGS approval in April 2026 expanded FILSPARI commercialization risk to a new indication
- Commercial execution risk increased with FSGS launch requiring further U.S. sales-force training
- MFN pricing executive order issued May 2025 could materially reduce product pricing
- Sole-source manufacturers for FILSPARI and Thiola heighten supply-disruption exposure
- France reimbursement dispute includes approximately $6.2 million paid while appeal continues
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Travere Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.